BTIM Corp. held its stake in Henry Schein, Inc. (NASDAQ:HSIC) during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 1,425 shares of the company’s stock at the end of the second quarter. BTIM Corp.’s holdings in Henry Schein were worth $261,000 as of its most recent filing with the SEC.
Other hedge funds have also recently added to or reduced their stakes in the company. Girard Partners LTD. boosted its stake in Henry Schein by 0.3% in the first quarter. Girard Partners LTD. now owns 3,115 shares of the company’s stock valued at $529,000 after buying an additional 10 shares during the last quarter. Cleararc Capital Inc. boosted its stake in Henry Schein by 0.6% in the first quarter. Cleararc Capital Inc. now owns 1,950 shares of the company’s stock valued at $331,000 after buying an additional 11 shares during the last quarter. Penserra Capital Management LLC boosted its stake in Henry Schein by 1.0% in the first quarter. Penserra Capital Management LLC now owns 1,518 shares of the company’s stock valued at $258,000 after buying an additional 15 shares during the last quarter. Wetherby Asset Management Inc. boosted its stake in Henry Schein by 0.7% in the first quarter. Wetherby Asset Management Inc. now owns 3,147 shares of the company’s stock valued at $535,000 after buying an additional 21 shares during the last quarter. Finally, Mn Services Vermogensbeheer B.V. boosted its stake in Henry Schein by 2.0% in the first quarter. Mn Services Vermogensbeheer B.V. now owns 2,147 shares of the company’s stock valued at $341,000 after buying an additional 43 shares during the last quarter. 90.87% of the stock is owned by institutional investors and hedge funds.
Shares of Henry Schein, Inc. (HSIC) opened at 170.58 on Friday. The company has a market cap of $13.49 billion, a price-to-earnings ratio of 24.93 and a beta of 1.09. The company’s 50-day moving average price is $181.54 and its 200-day moving average price is $175.12. Henry Schein, Inc. has a 12 month low of $146.23 and a 12 month high of $186.99.
Henry Schein (NASDAQ:HSIC) last released its earnings results on Tuesday, August 8th. The company reported $1.75 EPS for the quarter, beating the Zacks’ consensus estimate of $1.73 by $0.02. The business had revenue of $3.06 billion for the quarter, compared to analysts’ expectations of $3.05 billion. Henry Schein had a return on equity of 19.91% and a net margin of 4.59%. The firm’s revenue was up 6.4% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.64 earnings per share. Analysts anticipate that Henry Schein, Inc. will post $7.28 EPS for the current year.
TRADEMARK VIOLATION NOTICE: This piece was first posted by Community Financial News and is owned by of Community Financial News. If you are reading this piece on another publication, it was illegally copied and reposted in violation of U.S. & international trademark & copyright law. The legal version of this piece can be viewed at https://www.com-unik.info/2017/08/12/btim-corp-has-261000-stake-in-henry-schein-inc-nasdaqhsic-updated-updated.html.
Several analysts recently weighed in on the company. Jefferies Group LLC reissued a “hold” rating and set a $177.00 price target on shares of Henry Schein in a report on Friday, July 21st. Zacks Investment Research raised Henry Schein from a “hold” rating to a “buy” rating and set a $190.00 price target for the company in a report on Tuesday, April 25th. Stifel Nicolaus restated a “hold” rating on shares of Henry Schein in a research note on Thursday, July 6th. Barrington Research raised their price objective on Henry Schein from $196.00 to $198.00 and gave the stock an “outperform” rating in a research note on Wednesday, May 10th. Finally, BidaskClub lowered Henry Schein from a “hold” rating to a “sell” rating in a research note on Wednesday, August 2nd. One research analyst has rated the stock with a sell rating, ten have given a hold rating and seven have issued a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus target price of $185.56.
Henry Schein Company Profile
Henry Schein, Inc is a provider of healthcare products and services primarily to office-based dental, animal health and medical practitioners. The Company operates through two segments: healthcare distribution, and technology and value-added services. The healthcare distribution segment distributes consumable products, small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products and vitamins.
What are top analysts saying about Henry Schein Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Henry Schein Inc. and related companies.